Phase 1 First-in-human Study of JS014

Inclusion Criteria: * Older 18 years of age or per local regulation * Subjects with advanced cancer or lymphoma who have no standard therapy available, ineligible for standard therapy or unwilling to receive cytotoxic therapy . * ECOG PS 0-1 * A life expectancy longer than three months * Adequate organ functions * Able to adopt effective contraceptive measures Exclusion Criteria: * Known history of allergies to JS014 or IL-21 or human serum albumin or pembrolizumab (Ib only) * Subjects who have received major surgery less than 4 weeks before 1st infusion of JS014 * Subjects who has a history of immune-related adverse events in prior immunotherapy. * Subjects who have received immunosuppressive therapy less than 4 weeks before 1st infusion of JS014. * Subjects who have two or more primary cancers in the past 5 years. * Newly diagnosed or symptomatic brain metastases. * Subjects who have received prior anti-cancer therapy with residual toxicities greater than grade 2. * Subjects who have a history of autoimmune disease in 2 years. * Subjects who have active infection, or uncontrollable hypertension, unstable angina, active peptic ulcer, recent acute myocardial infarction, severe congestive heart failure, or unhealed wound. * Subjects with active hepatitis B or hepatitis C. * Subjects who are pregnant or breast feeding. * Subjects who primary immune deficiency.